Selective IgE immune apheresis hits market
Help for patients with IgE-mediated diseases
The product is an immune apheresis column which contains a single chain antibody fragment with very high affinity to human IgE, covalently linked to a solid support. The antibody ligand has been discovered in the laboratory of Prof. Rudolf Valenta at the Medical University of Vienna; Biomay holds the patent rights. Process development and GMP manufacturing of the affinity ligand has been performed by Biomay, while the device itself is manufactured and will be marketed by the development partner.
In a recently completed clinical trial the device has been shown to very efficiently and selectively remove IgE from the plasma of patients with allergic asthma. This trial was the basis of CE mark approval.
Biomay has already received several milestone payments and is entitled to royalties on sales.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.